Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

• Main Authors: Chen R, Chen B
• Format: Article
• Language: English
• Published: Dove Medical Press 2015-03-01
• Series: Drug Design, Development and Therapy
• Online Access: http://www.dovepress.com/brentuximab-vedotin-for-relapsed-or-refractory-hodgkinrsquos-lymphoma-peer-reviewed-article-DDDT

Runzhe Chen, Baoan Chen Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of China Abstract: Brentuximab vedotin is a promising antibody–drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refractory Hodgkin’s lymphoma (HL), and it has also shown its advantages in other CD30-positive lymphomas. In this review, we focus on the structure, mechanisms, and pharmacokinetics of brentuximab vedotin. We also summarize clinical trials with brentuximab vedotin and make recommendations for brentuximab vedotin in the treatment of relapsed or refractory HL. Keywords: lymphoma, CD30-positive, clinical trials, tumor cells, antitumor effects, monoclonal antibody